The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment
Abstract
To evaluate the clinical utility of recently developed biochemical markers of bone turnover to monitor the response of osteoporotic patients to antiresorptive therapy, we compared the results of three advanced assays for markers of bone resorption and four of bone formation to high pressure liquid chromatography (HPLC)-fluorometric assays for urinary pyridinoline and deoxypyridinoline. These assays were also used to resolve the uncertainties concerning the rate of bone turnover in late postmenopausal (late-PMP) osteoporotic women. The rate of bone turnover in 85 women (mean +/- SD age, 63 +/- 6 yr) with low bone mass and all more than 5 yr postmenopausal (mean +/- SD yr PMP, 16 +/- 7 yr) was compared to that in 46 premenopausal women (mean +/- SD age, 40 +/- 5 yr) randomly selected from a large cohort and all having a normal spine bone mineral density (BMD). The late-PMP osteoporotic patients were a subset of patients enrolled in a double blind, placebo-controlled, randomized study comparing the effects of several doses of oral alendronate, a potent and specific inhibitor of bone resorption. Periodically during the 2-yr study, the women's spinal BMD and the level of several markers of bone turnover were measured. Serum total and intact osteocalcin, bone-specific alkaline phosphatase, and carboxy-terminal propeptide of type I collagen measured by RIA were used to assess bone formation. To assess bone resorption, we measured the urinary excretion of total pyridinoline (HPLC Pyr) and deoxypyridinoline (HPLC D-Pyr) by HPLC, type I collagen cross-linked N-telopeptide and urinary free PYR (F-Pyr) by enzyme-linked immunosorbent assay, and the serum concentration of type I collagen cross-linked C-telopeptide (ICTP) by RIA. All bone formation markers, except carboxy-terminal propeptide of type I collagen, and all bone resorption markers, except ICTP, were significantly increased above normal (33-171%; P < 0.001) in late-PMP osteoporotic women. The long term within-patient variability assessed over a 15-month period in the placebo group was low and was somewhat lower for serum markers (12.5-17.4%) than for urinary markers (24-29%). Under treatment with alendronate, resorption markers decreased earlier than markers of bone formation, consistent with a direct action of the drug to inhibit osteoclastic bone resorption. With the exception of F-Pyr and ICTP, the levels of bone markers were reduced to the normal premenopausal range, and this steady state was maintained from 6-15 months.(ABSTRACT TRUNCATED AT 400 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parfitt, A. M., Mathews, C. H., Villanueva, A. R., Kleerekoper, M., Frame, B., & Rao, D. S. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111096 · Cited by 1,545
Long-term fracture prediction by bone mineral assessed at different skeletal sites
Dr. Melton, L. J., Atkinson, E. J., O'Fallon, W. M., Wahner, H. W., & Riggs, B. L. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650081010 · Cited by 862
Hanson, D. A., Weis, M. A. E., Bollen, A.-M., Maslan, S. L., Singer, F. R., & Dr. Eyre, D. R. (1992) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650071119 · Cited by 656
Risteli, J., Elomaa, I., Niemi, S., Novamo, A., & Risteli, L. (1993) · Clinical Chemistry · doi:10.1093/clinchem/39.4.635 · Cited by 622
ERIKSEN, E. F. (1986) · Endocrine Reviews · doi:10.1210/edrv-7-4-379 · Cited by 601
Which Fractures Are Associated with Low Appendicular Bone Mass in Elderly Women?
Seeley, D. G., Browner, W. S., Nevitt, M. C., Genant, H. K., Scott, J. C., Cummings, S. R., & Study of Osteoporotic Fractures Research Group (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-11-837 · Cited by 558
Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen
Melkko, J., Niemi, S., Risteli, L., & Risteli, J. (1990) · Clinical Chemistry · doi:10.1093/clinchem/36.7.1328 · Cited by 513
Black, D., Duncan, A., & Robins, S. P. (1988) · Analytical Biochemistry · doi:10.1016/0003-2697(88)90274-6 · Cited by 436
Uebelhart, D., Gineyts, E., Chapuy, M.-C., & Delmas, P. D. (1990) · Bone and Mineral · doi:10.1016/0169-6009(91)90143-n · Cited by 424
Mean wall thickness of trabecular bone packets in the human iliac crest: Changes with age
Lips, P., Courpron, P., & Meunier, P. J. (1978) · Calcified Tissue Research · doi:10.1007/bf02013227 · Cited by 411
Cited by
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,288
Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy
Odvina, C. V., Zerwekh, J. E., Rao, D. S., Maalouf, N., Gottschalk, F. A., & Pak, C. Y. C. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0952 · Cited by 1,432
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Self-citationfor the IOF-IFCC Bone Marker Standards Working Group, Vasikaran, S., Eastell, R., Bruyère, O., Foldes, A. J., Garnero, P., Griesmacher, A., McClung, M., Morris, H. A., Silverman, S., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1501-1 · Cited by 1,212
Self-citationChesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., Kiel, D., LeBoff, M., Maricic, M., Miller, P., et al. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00490-3 · Cited by 1,122
Bisphosphonates: The first 40years
Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2011.04.022 · Cited by 1,124
Bisphosphonates: Mechanisms of Action
Fleisch, H. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0325 · Cited by 1,019
Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis
Dr. Garnero, P., Sornay-Rendu, E., Chapuy, M.-C., & Delmas, P. D. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110307 · Cited by 1,001
Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study
Garnero, P., Hausherr, E., Chapuy, M.-C., Marcelli, C., Grandjean, H., Muller, C., Cormier, C., Bréart, G., Meunier, P. J., & Dr. Delmas, P. D. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650111021 · Cited by 989
Self-citationBisphosphonates: mechanisms of action.
Rodan, G. A., & Fleisch, H. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118722 · Cited by 921
Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density
Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U., Widmer, A., Devogelaer, J.-P., Kaufman, J.-M., Jaeger, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011807 · Cited by 877
Bisphosphonates: from the laboratory to the clinic and back again
Russell, R. G. G., & Rogers, M. J. (1999) · Bone · doi:10.1016/s8756-3282(99)00116-7 · Cited by 840
Intermittent Etidronate Therapy to Prevent Corticosteroid-Induced Osteoporosis
Adachi, J. D., Bensen, W. G., Brown, J., Hanley, D., Hodsman, A., Josse, R., Kendler, D. L., Lentle, B., Olszynski, W., Ste.-Marie, L.-G., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708073370603 · Cited by 685
Treatment of postmenopausal osteoporosis
Delmas, P. D. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08827-x · Cited by 681
Knott, L., & Bailey, A. J. (1998) · Bone · doi:10.1016/s8756-3282(97)00279-2 · Cited by 641
Treatment of Postmenopausal Osteoporosis
Eastell, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803123381107 · Cited by 615
Pols, H. A. P., Felsenberg, D., Hanley, D. A., Štepán, J., Muñoz-Torres, M., Wilkin, T. J., Qin-sheng, G., Galich, A. M., Vandormael, K., Yates, A. J., et al. (1999) · Osteoporosis International · doi:10.1007/pl00004171 · Cited by 593
Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate
Eastell, R., Barton, I., Hannon, R., Chines, A., Garnero, P., & Delmas, P. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.6.1051 · Cited by 588
Self-citationBiochemical Markers of Bone Metabolism: An Overview
Christenson, R. H. (1997) · Clinical Biochemistry · doi:10.1016/s0009-9120(97)00113-6 · Cited by 542
Chavassieux, P. M., Arlot, M. E., Reda, C., Wei, L., Yates, A. J., & Meunier, P. J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119668 · Cited by 523
Bisphosphonates: Mode of Action and Pharmacology
Russell, R. G. G. (2007) · Pediatrics · doi:10.1542/peds.2006-2023h · Cited by 503
Garnero, P., Ferreras, M., Karsdal, M., Nicamhlaoibh, R., Risteli, J., Borel, O., Qvist, P., Delmas, P., Foged, N., & Delaissé, J. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.5.859 · Cited by 472
Self-citationJournal of Bone and Mineral Research
Delmas, P. D. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650081323 · Cited by 454
HMG-CoA Reductase Inhibitors and the Risk of Fractures
Meier, C. R. (2000) · JAMA · doi:10.1001/jama.283.24.3205 · Cited by 445
Opposite Bone Remodeling Effects of Teriparatide and Alendronate in Increasing Bone Mass
McClung, M. R., San Martin, J., Miller, P. D., Civitelli, R., Bandeira, F., Omizo, M., Donley, D. W., Dalsky, G. P., & Eriksen, E. F. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1762 · Cited by 444
Bisphosphonates: From Bench to Bedside
RUSSELL, R. G. G. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1346.041 · Cited by 410
Bisphosphonates: An Update on Mechanisms of Action and How These Relate to Clinical Efficacy
RUSSELL, R. G. G., XIA, Z., DUNFORD, J. E., OPPERMANN, U., KWAASI, A., HULLEY, P. A., KAVANAGH, K. L., TRIFFITT, J. T., LUNDY, M. W., PHIPPS, R. J., et al. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.089 · Cited by 391
Bone Turnover Markers: Basic Biology to Clinical Applications
Schini, M., Vilaca, T., Gossiel, F., Salam, S., & Eastell, R. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac031 · Cited by 387
Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study
Lenart, B. A., Neviaser, A. S., Lyman, S., Chang, C. C., Edobor-Osula, F., Steele, B., van der Meulen, M. C. H., Lorich, D. G., & Lane, J. M. (2009) · Osteoporosis International · doi:10.1007/s00198-008-0805-x · Cited by 384
The Assessment of Fracture Risk
Unnanuntana, A., Gladnick, B. P., Donnelly, E., & Lane, J. M. (2010) · The Journal of Bone and Joint Surgery-American Volume · doi:10.2106/jbjs.i.00919 · Cited by 361
Relationship of Bone Turnover to Bone Density and Fractures
Melton, L. J., Khosla, S., Atkinson, E. J., O'Fallon, W. M., & Riggs, B. L. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.7.1083 · Cited by 350
Associated Loss of Fat-free Mass and Bone Mineral Density in Chronic Obstructive Pulmonary Disease
Bolton, C. E., Ionescu, A. A., Shiels, K. M., Pettit, R. J., Edwards, P. H., Stone, M. D., Nixon, L. S., Evans, W. D., Griffiths, T. L., & Shale, D. J. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200406-754oc · Cited by 337
Clinical Utility of Biochemical Markers of Bone Remodeling
Watts, N. B. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.8.1359 · Cited by 336
Chapuy, M. C. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.3.1129 · Cited by 334
MECHANISMS OF ACTION OF BISPHOSPHONATES
Rodan, G. A. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.375 · Cited by 304
Pharmacokinetics of Alendronate
Porras, A. G., Holland, S. D., & Gertz, B. J. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936050-00002 · Cited by 296
Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal Osteoporosis
Khan, S. A., Kanis, J. A., Vasikaran, S., Kline, W. F., Matuszewski, B. K., McCloskey, E. V., Beneton, M. N. C., Gertz, B. J., Sciberras, D. G., Holland, S. D., et al. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.10.1700 · Cited by 293
Bone turnover markers and bone density across the menopausal transition.
Ebeling, P. R., Atley, L. M., Guthrie, J. R., Burger, H. G., Dennerstein, L., Hopper, J. L., & Wark, J. D. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.9.8784098 · Cited by 293
Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate
Blake, G. M., Park-Holohan, S.-J., Cook, G. J. R., & Fogelman, I. (2001) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2001.18742 · Cited by 286
Chesnut, C. H., Bell, N. H., Clark, G. S., Drinkwater, B. L., English, S. C., Johnston, C. C., Notelovitz, M., Rosen, C., Cain, D. F., Flessland, K. A., et al. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00387-7 · Cited by 282
Prevention of Nonvertebral Fractures by Alendronate: A Meta-analysis
Karpf, D. B. (1997) · JAMA · doi:10.1001/jama.1997.03540380073035 · Cited by 281
The pharmacology of bisphosphonates and new insights into their mechanisms of action
Russell, R. G. G., Rogers, M. J., Frith, J. C., Luckman, S. P., Coxon, F. P., Benford, H. L., Croucher, P. I., Shipman, C., & Fleisch, H. A. (1999) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650140212 · Cited by 279
(BONE), F. T. O. I. O. V. F. T. I. N. A. A. E., Delmas, P. D., Recker, R. R., Chesnut, C. H., Skag, A., Stakkestad, J. A., Emkey, R., Gilbride, J., Schimmer, R. C., & Christiansen, C. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1602-9 · Cited by 279
Regulation of TNF-Induced Osteoclast Differentiation
Yao, Z., Getting, S. J., & Locke, I. C. (2021) · Cells · doi:10.3390/cells11010132 · Cited by 280
Grinspoon, S. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.11.3864 · Cited by 258
Hannon, R., Blumsohn, A., Naylor, K., & Eastell, R. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.7.1124 · Cited by 257
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis
Eastell, R., Christiansen, C., Grauer, A., Kutilek, S., Libanati, C., McClung, M. R., Reid, I. R., Resch, H., Siris, E., Uebelhart, D., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.251 · Cited by 256
Meaney, A. M., & O'Keane, V. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.01.013 · Cited by 92
Stone, J. A., McCrea, J. B., Witter, R., Zajic, S., & Stoch, S. A. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13869 · Cited by 66
Bone turnover markers and sex hormones in men with idiopathic osteoporosis
Pietschmann, P., Kudlacek, S., Grisar, J., Spitzauer, S., Woloszczuk, W., Willvonseder, R., & Peterlik, M. (2001) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2001.00836.x · Cited by 62
Effects of phytoestrogens on bone turnover in postmenopausal women with a history of breast cancer
Nikander, E., Metsä-Heikkilä, M., Ylikorkala, O., & Tiitinen, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031166 · Cited by 56
Metadata
- Authors
- Garnero, P.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1994-12-01
- Volume
- 79
- Issue
- 6
- Pages
- 1693-1700
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2101280309
- Cited by
- 707
- References
- 30
- FWCI
- 45.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.